What Viiral does

Viiral AS is a Norwegian private limited company that develops and commercializes a single physical health product, the Viiral Nasal Spray, intended to protect against virus infections in the upper airways by keeping the nasal mucous membranes moist. The company was founded in Norway in 2020 and operates with a small team (1-10 employees) under founder/management ownership, with Jan Remmereit as Founder and Board member and Ola Røthe serving in a CEO/Chairman capacity. The product is supported by a published in-vitro study from Umeå University showing 80-100% inhibition of transduction for Corona-43 and common cold viruses, an ongoing preventive-effect investigation at the Norwegian University of Science and Technology, and a planned Post-Market Clinical Follow-up study for dry-nose symptoms. No patents, trademarks, regulatory certifications, or AI/ML components are disclosed in the available material, and the website currently lists the product as "Available soon" with no public pricing.

The business model is asset-light and partner-driven: Viiral does not run its own direct sales operation but instead distributes the nasal spray through a small set of named regional channel partners, each holding exclusive rights to a defined geography. Avia Pharma covers Sweden, Denmark, Finland, and Norway; Jaber BV covers Belgium, the Netherlands, Luxembourg, and Germany; Aurora Biotech LTD covers China; and Nordic wellness LTD covers India. Middle East activity is referenced in scale commentary but no named partner is disclosed. End customers are health-conscious consumers seeking non-pharmaceutical preventive measures for upper respiratory health, reached through the partners' retail and pharmacy channels. The company is privately held with no institutional funding, venture capital investment, or acquisition history disclosed, and operates with headquarters in Norway.

Name

Viiral

Legal name

Viiral AS

Website

https://viiral.no

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Viiral AS is a Norwegian health-products company that has developed a nasal spray intended to protect against upper-airway virus infections, distributed via regional channel partners across Europe, Asia, and the Middle East to health-conscious consumers.

Ownership category

akta.pro rank

Product category

Respiratory Health Products

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industry

Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

Keywords

• Nasal spray products
• Virus prevention
• Respiratory health
• Marine-based supplements
• Pharmaceutical distribution

Headquarters

HQ city

Ålesund

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Nasal Spray Product Sales: Revenue generated from the sale of Viiral Nasal Spray products. The product is positioned as a protective measure against virus infections.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels1 record

Core offering

Viiral develops and sells a single physical product, the Viiral Nasal Spray, a nasal spray formulation designed to protect against virus infections in the upper airways by keeping the mucous membranes moist. The product is targeted at health-conscious consumers seeking non-pharmaceutical preventive measures for respiratory and nasal health, and is distributed through regional pharmaceutical and wellness partners across Europe, Asia, and the Middle East.

Product overview

Viiral offers a single unified product: the Viiral Nasal Spray. This product is a nasal spray intended to protect against virus infections in the upper airways by keeping the mucous membranes moist, which ENT doctors consider an important preventive measure against viruses entering through the nasal mucosa. The company operates as a health products business with distribution partners across Europe, Asia, and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

• Viiral Nasal Spray: A nasal spray product designed to protect against virus infections in the upper airways by keeping mucous membranes moist.

Products and services

• Viiral Nasal Spray A nasal spray product designed to protect against virus infections in the upper airways and help maintain a healthy nose by keeping mucous membranes moist, which ENT doctors identify as one of the most important measures to prevent viruses from entering through the nasal mucosa. Targeted at health-conscious individual consumers.

Quantifiable outcome

• In-vitro study shows 80-100% inhibition of virus transduction for Corona-43 and common cold viruses

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• Avia PharmacoreChannel Partner/ Reseller/ DistributorAvia Pharma serves as the distribution partner for Viiral in Sweden, Denmark, Finland, and Norway. Contact is Suzanne Ceder, Business Director OTC, Phone: +46 70888 05 45.
• Jaber BVcoreChannel Partner/ Reseller/ DistributorJaber BV serves as the distribution partner for Viiral in Belgium, the Netherlands, Luxembourg, and Germany. Contact is Berry Koldewijn, CEO, [email protected], Phone: +31 352031931 / +31 651507736.
• Aurora Biotech LTDcoreChannel Partner/ Reseller/ DistributorAurora Biotech LTD serves as the distribution partner for Viiral in China. Contact is Leo Guo, General Manager, [email protected].
• Nordic wellness LTDcoreChannel Partner/ Reseller/ DistributorNordic wellness LTD serves as the distribution partner for Viiral in India. Contact is Johan F Aasen, [email protected], Phone: +47 917 95 798.

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Bayer Consumer Health: Bayer's consumer health division operates Bepanthen, Rhinomer and other nasal/respiratory OTC brands across Europe and emerging markets. As a deep-pocketed OTC incumbent active in the same European retail channels Viiral targets via Jaber BV and Avia Pharma, it is a relevant scaled peer.
• Church & Dwight: Church & Dwight owns the Arm & Hammer 'Simply Saline' nasal-spray line plus Batiste and other consumer health brands. As a large CPG incumbent with established retail distribution in nasal care, it is a comparable benchmark for what scaled nasal-spray commercialization looks like.
• NeilMed Pharmaceuticals: NeilMed is the dominant saline nasal-rinse and nasal-spray brand globally, sold in pharmacies and retail. It competes directly with Viiral for shelf space and consumer mindshare in the daily-use nasal hygiene category, albeit on a saline rather than virus-inhibition positioning.
• GSK Consumer Healthcare: GSK markets Otrivin (xylometazoline) and other nasal-respiratory OTC brands globally. As a leading OTC respiratory player with pharmacy-channel dominance, it is a relevant comparator for category economics, regulatory positioning and consumer education spend.
• Prestige Consumer Healthcare: Prestige Consumer Healthcare owns NeilMed along with a portfolio of OTC respiratory and personal-care brands. It represents the strategic acquirer / scaled competitor profile for a small nasal-spray company looking to monetize distribution into US pharmacy retail.
• Sterling Healthcare: Sterling Healthcare markets NasoGel and related nasal moisturizing sprays targeted at dry-nose symptoms — the same primary use case Viiral's PMCF trial is investigating. It competes for the same chronic dry-nose consumer segment in pharmacy channels.

Direct peers

• Xlear: Xlear sells xylitol-based nasal sprays marketed for nasal hygiene and as a natural adjunct against airborne viruses and bacteria. It is the closest natural-positioning nasal-spray competitor to Viiral, with overlapping mechanism (moistening/inhibition at the nasal mucosa) and similar consumer health target.

Regional players

• HydraSense (Church & Dwight): HydraSense is a saline nasal-spray brand primarily distributed in Canada and parts of Europe. It overlaps directly with Viiral's product category in selected European markets where Viiral's Jaber BV and Avia Pharma partners operate.
• Stérimar (Church & Dwight): Stérimar is a seawater-based nasal spray brand widely sold across European pharmacies. It competes in the same natural/saline nasal hygiene segment Viiral targets, particularly in DACH and Benelux where Jaber BV is Viiral's regional partner.

Emerging players

• SaNOtize: SaNOtize developed a nitric-oxide releasing nasal spray (NONS / Enovid) positioned to kill viruses in the nasal cavity. Like Viiral, it is an early-stage company making virus-prevention claims via a nasal-spray delivery mechanism and competing for the same post-COVID preventive respiratory narrative.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viiral